MSLN was discovered in the mid-1990s, in an investigation initiated by Ira Pastan and Mark Willingham (National Cancer Institute, NIH) aiming to find new therapeutic target to treat ovarian cancer, where they started by screening for novel antibodies that target proteins significantly overexpressed in cancer cells compared to normal cells (102). Here, MSLN is linked to ovarian carcinoma.